Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.
作者信息
González Sanchidrián Silvia, Gallego Domínguez Sandra, Jiménez Mayor Elena, Labrador Gómez Pedro Jesús, Deira Lorenzo Javier
机构信息
Servicio de Nefrología, Hospital San Pedro de Alcántara, Complejo Hospitalario Universitario de Cáceres, Cáceres, Spain.
Servicio de Nefrología, Hospital San Pedro de Alcántara, Complejo Hospitalario Universitario de Cáceres, Cáceres, Spain.
出版信息
Nefrologia (Engl Ed). 2024 May-Jun;44(3):442-444. doi: 10.1016/j.nefroe.2023.10.009. Epub 2024 Jun 12.
PMID:38871561
Abstract
摘要
相似文献
1
Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.度拉糖肽在一名接受递增式腹膜透析的糖尿病肥胖患者中的应用经验。
Nefrologia (Engl Ed). 2024 May-Jun;44(3):442-444. doi: 10.1016/j.nefroe.2023.10.009. Epub 2024 Jun 12.
2
Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter.
Nefrologia (Engl Ed). 2024 May-Jun;44(3):444-446. doi: 10.1016/j.nefroe.2023.10.010. Epub 2024 Jun 10.
3
[Dulaglutide and liraglutide compared].[度拉糖肽与利拉鲁肽的比较]
Med Monatsschr Pharm. 2015 May;38(5):198-9.
4
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.度拉糖肽（度易达）用于2型糖尿病
Am Fam Physician. 2017 Oct 15;96(8):540-542.
5
Two new doses of dulaglutide (Trulicity) for diabetes.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):168.
6
The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.度拉糖肽对血液透析的 2 型糖尿病患者身体成分的影响。
J Diabetes Complications. 2018 Aug;32(8):759-763. doi: 10.1016/j.jdiacomp.2018.05.018. Epub 2018 Jun 1.
7
Dulaglutide: first global approval.度拉糖肽：全球首次获批。
Drugs. 2014 Nov;74(17):2097-103. doi: 10.1007/s40265-014-0320-7.
8
Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.基线特征对中国2型糖尿病患者在基础胰岛素治疗中加用度拉鲁肽疗效的影响：AWARD-CHN3亚组分析
Diabetes Obes Metab. 2024 Apr;26(4):1540-1543. doi: 10.1111/dom.15416. Epub 2024 Jan 7.
9
A promising outlook for diabetic kidney disease.糖尿病肾病的前景乐观。
Nat Rev Nephrol. 2019 Feb;15(2):68-70. doi: 10.1038/s41581-018-0092-5.
10
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.度拉鲁肽与 2 型糖尿病患者的肾脏结局：REWIND 随机、安慰剂对照试验的探索性分析。
Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.
Zotero 插件